Orforglipron and Grapefruit: Does It Interact With Foundayo?

Grapefruit doesn’t get named in the FDA-approved FOUNDAYO label, but the mechanism behind the classic “grapefruit warning” on other medications is relevant to orforglipron for a real reason: it’s metabolized partly through the CYP3A4 enzyme pathway, and the label does set specific dosing rules around strong CYP3A4 inhibitors and inducers. Here’s what the label actually addresses, how grapefruit fits into that picture, and what it doesn’t settle.

Does orforglipron interact with grapefruit?

Not by name. The FOUNDAYO label doesn’t list grapefruit or grapefruit juice as a restricted food. But orforglipron is metabolized in part via CYP3A4, and grapefruit is a well-documented CYP3A4 inhibitor — so the underlying mechanism for a possible interaction exists even though it isn’t spelled out on the label. That distinction — a plausible mechanism without a named warning — is the honest answer, not a simple yes or no.

Why grapefruit comes up for a GLP-1 pill in the first place

Most people associate the grapefruit-and-medication warning with statins or blood pressure drugs, not GLP-1 medications — and for injectable or oral peptide GLP-1s, that association doesn’t apply. Semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro, Zepbound) are peptides, broken down through general protein metabolism, per their MedlinePlus drug information — not through the liver’s CYP enzyme system.

Orforglipron is different. It’s a small-molecule GLP-1 receptor agonist, and per its FDA-approved label on DailyMed, it’s metabolized in part via CYP3A4, an enzyme pathway shared with many other oral drugs. Grapefruit and grapefruit juice are well-established intestinal CYP3A4 inhibitors — a long-documented pharmacology fact behind warnings on statins, certain blood pressure medications, and others. That’s the mechanism that makes the question “does grapefruit interact with orforglipron” a reasonable one to ask, even though the label doesn’t name grapefruit specifically.

If you want the fuller picture of why orforglipron behaves differently from peptide GLP-1s pharmacologically, How Long Does Orforglipron Stay in Your System? covers its CYP3A4-driven metabolism and half-life in more detail.

What the FOUNDAYO label actually says about CYP3A4

The label doesn’t leave CYP3A4 interactions unaddressed — it just addresses them in terms of named drug categories and specific medications, not grapefruit. Per the FDA-approved label on DailyMed:

• Strong CYP3A4 inhibitors: cap orforglipron’s dose at 9 mg once daily when taken together.
• Strong CYP3A4 inhibitors that also inhibit the OATP1B transporter: avoid combining with orforglipron.
• Strong CYP3A4 inducers: avoid combining with orforglipron, since inducers can lower orforglipron’s effectiveness.
• Simvastatin: cap at 20 mg once daily when taken with orforglipron.

That’s a real, specific set of interaction rules — it just isn’t framed around grapefruit the way some older statin labels are. Grapefruit juice is generally classified as a moderate intestinal CYP3A4 inhibitor rather than a strong one in the pharmacology literature, which may be part of why it isn’t named outright. But “moderate” and “not studied for this specific drug” aren’t the same as “confirmed no effect.”

At a glance

Factor	What’s actually known
Grapefruit named in FOUNDAYO label	No — not addressed by name
CYP3A4 metabolism	Yes, per the label’s pharmacokinetics section
Strong CYP3A4 inhibitor rule	Cap orforglipron at 9 mg/day
Strong CYP3A4 inhibitor + OATP1B inhibitor	Avoid combination
Strong CYP3A4 inducer rule	Avoid combination
Named drug example	Simvastatin capped at 20 mg/day with orforglipron
Same concern for Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound	No — these are peptides, not CYP3A4-metabolized

Sources: FOUNDAYO FDA label (DailyMed) and MedlinePlus semaglutide/tirzepatide drug information, linked below.

What this means in practice

There’s no label-based instruction telling you to avoid grapefruit entirely, and this article isn’t going to invent one where the label doesn’t. What’s actually useful is narrower:

• If you eat grapefruit or drink grapefruit juice regularly, mention it to your prescriber or pharmacist before or soon after starting orforglipron. They can weigh your actual intake against the label’s CYP3A4 guidance in a way a general article can’t.
• If you’re prescribed a strong CYP3A4 inhibitor or inducer for another condition, that’s the interaction the label actually quantifies — bring your full medication list so your prescriber can apply the 9 mg cap, the OATP1B caution, or the inducer guidance correctly. Orforglipron Drug Interactions covers the broader interaction picture beyond CYP3A4 specifically.
• If you’re on simvastatin already, the label does set a specific 20 mg cap when combined with orforglipron — worth confirming directly with your prescriber rather than assuming your current statin dose is unaffected. Orforglipron and Statins goes into the statin side of this in more depth.
• Don’t extend this concern to injectable or Rybelsus-style oral semaglutide, or to tirzepatide — the CYP3A4 pathway orforglipron uses doesn’t apply to those peptide drugs.
• If you’re newly starting orforglipron, review the rest of its labeled side effects and precautions too — Orforglipron Side Effects covers the broader picture beyond this one interaction question.

What this article won’t do

It won’t tell you grapefruit is confirmed safe with orforglipron, and it won’t tell you it’s dangerous — neither claim is something the FOUNDAYO label supports directly, since grapefruit isn’t named in it. It also won’t attach a specific percentage change in drug levels to grapefruit and orforglipron together, because no verified clinical study on that exact combination exists for this article to cite. The honest answer sits in between: the mechanism for a possible interaction is real and label-supported (CYP3A4 metabolism), but the direct evidence connecting grapefruit specifically to orforglipron levels hasn’t been published.

Bottom line

Orforglipron’s FDA label doesn’t mention grapefruit by name, but it does establish that orforglipron is metabolized via CYP3A4 and sets real dosing rules — a 9 mg cap with strong CYP3A4 inhibitors, avoidance with strong inhibitors that also hit OATP1B, avoidance with strong inducers, and a 20 mg simvastatin cap. Grapefruit’s well-documented role as a CYP3A4 inhibitor makes it reasonable to ask about, even without a named warning. If grapefruit is a regular part of your diet, raise it with your prescriber or pharmacist when you start orforglipron, rather than assuming “not on the label” means “not worth mentioning.”

For the full dosing and administration picture, see Foundayo (Orforglipron): A Simple Guide.